Courtesy of Novartis
Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin (treprostinil) hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Sandoz, United Therapeutics, Remodulin, patent validity, ANDA